LiMAx Test Shows Reversibility of Fatty Liver Disease After Obesity Surgery
News Sep 15, 2015
Humedics GmbH has announced results of a clinical study performed at the RWTH Aachen University Hospital. The aim of the study was to assess alterations in liver function capacity with the LiMAx test after bariatric surgery of obese patients. Study results demonstrated that fatty liver disease is reversible after weight reduction and that the LiMAx test is a reliable tool to measure functional liver recovery after obesity surgery.
The prevalence of overweight and obesity has increased dramatically in recent years. Approximately half or more than half of the Western world’s population is overweight or obese. The hepatic manifestation of the metabolic syndrome is nonalcoholic fatty liver disease (NAFLD), which is presently considered to be the most common liver disease in Western countries.
NAFLD may progress to nonalcoholic steatohepatitis (NASH) and liver fibrosis. Both, NAFLD and NASH are reversible when effective weight reduction can be achieved. However, current noninvasive approaches to diagnosis, staging, and management of NAFLD and NASH are deficient.
Bariatric surgery provides long-term weight loss and improvement of obesity-associated liver diseases. In a prospective cohort study from October 2011 to May 2014, morbidly obese individuals receiving bariatric surgery were investigated for functional liver recovery. Liver function was determined by the LiMAx test preoperatively, 6 and 12 months postoperatively.
Investigator Prof. Ulf Neumann, Department of General, Visceral and Transplantation Surgery, RWTH Aachen University Hospital, said: “We applied the LiMAx test to assess the liver function of morbidly obese patients and to monitor the functional liver recovery after bariatric surgery. The non-invasive LiMAx breath test validly determines liver function capacity. It may avoid the inaccuracy seen with blood parameters and the risks of invasive liver biopsies which, moreover, do not necessarily reflect the liver function. Our study results show that LiMAx values correlate to the NAFLD activity score (NAS). Thus, the LiMAx test is an interesting method to diagnose and monitor NAFLD and NASH.”
Study results showed that the mean liver function capacity significantly increased from preoperatively severely impaired values to normal values within 6 months after surgery and further improved over the period of the survey with a final measurement after one year.
Erwin de Buijzer, CEO of Humedics GmbH, stated: “The study at the Aachen University Hospital clearly demonstrated the usefulness of our LiMAx test in obesity-related liver diseases and represents the first study to noninvasively assess the impact of weight loss on changes in the liver function. The dramatic increase of obesity and obesity-associated diseases is a major problem in the Western world. We are very pleased to provide physicians with a novel diagnostic test to better assess obesity patients and to monitor disease course and therapy success.”
The LiMAx test, together with the corresponding FLIP device and the diagnostic drug offers a clinically proven significant added value for patients with liver diseases and liver surgery.
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
CBD Significantly Reduces Seizures in Patients with Severe Form of EpilepsyNews
Large-scale clinical trial finds cannabidiol can dramatically reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.